Pharmacogenetics and interstitial lung disease

Justin Oldham, Imre Noth, Fernando J. Martinez

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Purpose of review Interstitial lung disease (ILD) is comprised of a heterogeneous group of disorders with highly variable natural histories and response to therapies. Pharmacogenetics focuses on the variability in drug response because of the presence of genetic factors that influence drug metabolism or disease activity. In this article, we review relevant drug-specific and disease-specific polymorphisms that may influence therapeutic response, and then highlight a recently identified drug-gene interaction in patients with idiopathic pulmonary fibrosis (IPF). Recent findings The emergence of high-throughput genomic technology has allowed for identification of gene polymorphisms associated with susceptibility to specific disease states, including IPF and several connective tissue diseases known to cause ILD. IPF risk loci span a diverse group of genes, while most associated with connective tissue disease are critical to immune signaling. A recent pharmacogenetic analysis of patients enrolled in an IPF clinical trial identified a variant within TOLLIP to be associated with differential response to N-acetylcysteine therapy. Summary Though few pharmacogenetic investigations have been conducted in patients with ILD to date, ample opportunities for pharmacogenetic exploration exist in this patient population. Such exploration will advance our understanding of specific ILDs and help usher in an era of personalized medicine.

Original languageEnglish (US)
Pages (from-to)456-465
Number of pages10
JournalCurrent Opinion in Pulmonary Medicine
Volume22
Issue number5
DOIs
StatePublished - Sep 1 2016

Fingerprint

Idiopathic Pulmonary Fibrosis
Pharmacogenetics
Interstitial Lung Diseases
Connective Tissue Diseases
Pharmaceutical Preparations
Genes
Precision Medicine
Acetylcysteine
Natural History
Drug Interactions
Therapeutics
Clinical Trials
Technology
Population

Keywords

  • connective tissue disease
  • idiopathic pulmonary fibrosis
  • interstitial lung disease
  • pharmacogenetics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Pharmacogenetics and interstitial lung disease. / Oldham, Justin; Noth, Imre; Martinez, Fernando J.

In: Current Opinion in Pulmonary Medicine, Vol. 22, No. 5, 01.09.2016, p. 456-465.

Research output: Contribution to journalReview article

Oldham, Justin ; Noth, Imre ; Martinez, Fernando J. / Pharmacogenetics and interstitial lung disease. In: Current Opinion in Pulmonary Medicine. 2016 ; Vol. 22, No. 5. pp. 456-465.
@article{7322494a7f8b4454a06897c87742e42b,
title = "Pharmacogenetics and interstitial lung disease",
abstract = "Purpose of review Interstitial lung disease (ILD) is comprised of a heterogeneous group of disorders with highly variable natural histories and response to therapies. Pharmacogenetics focuses on the variability in drug response because of the presence of genetic factors that influence drug metabolism or disease activity. In this article, we review relevant drug-specific and disease-specific polymorphisms that may influence therapeutic response, and then highlight a recently identified drug-gene interaction in patients with idiopathic pulmonary fibrosis (IPF). Recent findings The emergence of high-throughput genomic technology has allowed for identification of gene polymorphisms associated with susceptibility to specific disease states, including IPF and several connective tissue diseases known to cause ILD. IPF risk loci span a diverse group of genes, while most associated with connective tissue disease are critical to immune signaling. A recent pharmacogenetic analysis of patients enrolled in an IPF clinical trial identified a variant within TOLLIP to be associated with differential response to N-acetylcysteine therapy. Summary Though few pharmacogenetic investigations have been conducted in patients with ILD to date, ample opportunities for pharmacogenetic exploration exist in this patient population. Such exploration will advance our understanding of specific ILDs and help usher in an era of personalized medicine.",
keywords = "connective tissue disease, idiopathic pulmonary fibrosis, interstitial lung disease, pharmacogenetics",
author = "Justin Oldham and Imre Noth and Martinez, {Fernando J.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1097/MCP.0000000000000289",
language = "English (US)",
volume = "22",
pages = "456--465",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Pharmacogenetics and interstitial lung disease

AU - Oldham, Justin

AU - Noth, Imre

AU - Martinez, Fernando J.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Purpose of review Interstitial lung disease (ILD) is comprised of a heterogeneous group of disorders with highly variable natural histories and response to therapies. Pharmacogenetics focuses on the variability in drug response because of the presence of genetic factors that influence drug metabolism or disease activity. In this article, we review relevant drug-specific and disease-specific polymorphisms that may influence therapeutic response, and then highlight a recently identified drug-gene interaction in patients with idiopathic pulmonary fibrosis (IPF). Recent findings The emergence of high-throughput genomic technology has allowed for identification of gene polymorphisms associated with susceptibility to specific disease states, including IPF and several connective tissue diseases known to cause ILD. IPF risk loci span a diverse group of genes, while most associated with connective tissue disease are critical to immune signaling. A recent pharmacogenetic analysis of patients enrolled in an IPF clinical trial identified a variant within TOLLIP to be associated with differential response to N-acetylcysteine therapy. Summary Though few pharmacogenetic investigations have been conducted in patients with ILD to date, ample opportunities for pharmacogenetic exploration exist in this patient population. Such exploration will advance our understanding of specific ILDs and help usher in an era of personalized medicine.

AB - Purpose of review Interstitial lung disease (ILD) is comprised of a heterogeneous group of disorders with highly variable natural histories and response to therapies. Pharmacogenetics focuses on the variability in drug response because of the presence of genetic factors that influence drug metabolism or disease activity. In this article, we review relevant drug-specific and disease-specific polymorphisms that may influence therapeutic response, and then highlight a recently identified drug-gene interaction in patients with idiopathic pulmonary fibrosis (IPF). Recent findings The emergence of high-throughput genomic technology has allowed for identification of gene polymorphisms associated with susceptibility to specific disease states, including IPF and several connective tissue diseases known to cause ILD. IPF risk loci span a diverse group of genes, while most associated with connective tissue disease are critical to immune signaling. A recent pharmacogenetic analysis of patients enrolled in an IPF clinical trial identified a variant within TOLLIP to be associated with differential response to N-acetylcysteine therapy. Summary Though few pharmacogenetic investigations have been conducted in patients with ILD to date, ample opportunities for pharmacogenetic exploration exist in this patient population. Such exploration will advance our understanding of specific ILDs and help usher in an era of personalized medicine.

KW - connective tissue disease

KW - idiopathic pulmonary fibrosis

KW - interstitial lung disease

KW - pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=84973160652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973160652&partnerID=8YFLogxK

U2 - 10.1097/MCP.0000000000000289

DO - 10.1097/MCP.0000000000000289

M3 - Review article

C2 - 27253772

AN - SCOPUS:84973160652

VL - 22

SP - 456

EP - 465

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 5

ER -